Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (3,826,000)	$ (3,306,000)	$ (13,281,000)	$ (10,466,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment			484,000	500,000
Redeemable warrants valuation adjustment			(22,000)	120,000
Warrant modification				46,000
Extinguishment of financing obligation and note payable			2,701,000	142,000
Amortization of patent, trademark rights			97,000	41,000	$ 158,000
Changes in ROU assets			35,000	(36,000)
Gain on sale of property and equipment			(216,000)
Gain from sale of income tax operating losses	(72,000)		(542,000)
Equity-based compensation			1,320,000	596,000
Realized (loss) gain on sale of marketable securities			126,000	(12,000)
Amortization of finance and debt issuance costs			47,000	77,000
Change in assets and liabilities:
Accounts receivable			6,000	18,000
Funds Receivable from New Jersey net operating loss			1,090,000	776,000
Prepaid expenses and other current assets and other non-current assets			64,000	764,000
Lease liability			(35,000)	36,000
Accounts payable			(14,000)	(265,000)
Accrued interest expense				230,000
Accrued expenses			(80,000)	(81,000)
Net cash used in operating activities			(8,220,000)	(7,514,000)
Cash flows from investing activities:
Proceeds from sale of marketable securities			849,000	8,497,000
Purchase of marketable securities			(1,611,000)	(17,169,000)
Purchase of property and equipment			(34,000)	(13,000)
Proceeds from sale of property and equipment			245,000
Purchase of patent and trademark rights			(444,000)	(297,000)
Net cash used in investing activities			(995,000)	(8,982,000)
Cash flows from financing activities:
Payment on note payable				(4,279,000)
Payment of financing obligation			(4,732,000)
Financing obligation payments			(122,000)	(265,000)
Proceeds from sale of stock, net of issuance costs			12,917,000	58,066,000
Net cash provided by financing activities			8,063,000	53,522,000
Net (decrease) increase in cash and cash equivalents			(1,152,000)	37,026,000
Cash and cash equivalents at beginning of period			38,501,000	1,470,000	1,470,000
Cash and cash equivalents at end of period	$ 37,349,000	$ 38,496,000	37,349,000	38,496,000	$ 38,501,000
Supplemental disclosures of non-cash investing and financing cash flow information:
Stock issued to settle accounts payable				20,000
Unrealized loss on marketable securities			(329,000)	(12,000)
Conversion of Series B preferred			$ 7,000	$ 45,000